Status: Recruiting
Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia
The study objective is to evaluate patient safety for patients with refractory and relapsed AML being treated with Ceramide NanoLiposome (CNL) .
Participants needed: 15
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Keystone Nano, IncUpdated: Mar 31, 2026Locations: 1
Eligibility criteria
Signed informed consent is obtained prior to conducting any study-specific scree... [+9]
Uncontrolled intercurrent illness including, but not limited to, symptomatic con... [+10]